Norwood J, et al. - Researchers here determined weight change in patients with sustained virologic suppression who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor (INSTI)-containing regimen. They observed significantly more weight gain among adults living with HIV with viral suppression after switching from daily, fixed-dose EFV/TDF/FTC to an INSTI-based regimen compared with those remaining on EFV/TDF/FTC. Greatest weight gain was observed among patients switching to dolutegravir/abacavir/lamivudine.